ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
129.320,96
0,00%
S&P 500
5.631,22
0,28%
US Dollar vs BRL
5,4491
0,01%
Bitcoin
63.775,06
-1,66%
Brent Oil
83,01
-1,58%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Allos Therapeutics, Inc. (MM) (ALTH)

  7. Allos Therapeutics, Inc. (MM) (ALTH) Notícias

ALTH

Allos Therapeutics, Inc. (MM) (ALTH)

Allos Therapeutics, Inc. (MM)
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ALTH
DataHoraFonteTítuloCódigoCompanhia
17/06/201010:00Business WireAllos Therapeutics' Pralatrexate Granted Orphan Medicinal Product Designation for the Treatment of Cutaneous T-Cell Lymphoma ...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
11/06/201012:45Business WireAllos Therapeutics’ FOLOTYN Shows Activity & Tolerability in Phase 1 Dose Finding Study in Patients with Relapsed or Refrac...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
05/06/201010:00Business WireAllos Therapeutics Reports New Data Demonstrating that Responses to FOLOTYN are Correlated with Prolonged Survival in Patient...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
04/06/201010:00Business WireAllos Therapeutics to Present at Four Upcoming Investor ConferencesNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/06/201010:14Edgar (US Regulatory)Current report filing (8-K)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
01/06/201010:00Business WireAllos Therapeutics Announces FOLOTYN® Data Presentations at the American Society of Clinical Oncology & the Congress of the ...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
20/05/201010:00Business WireAllos Therapeutics to Present at the Citi Investment Research Global Health Care ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
18/05/201009:52Dow Jones NewsAllos Gets Orphan-Drug Designation For Bladder Cancer DrugNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
18/05/201009:00Business WireAllos Therapeutics’ Pralatrexate Granted FDA Orphan Drug Designation for the Treatment of Bladder CancerNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
12/05/201018:53Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
10/05/201016:42Edgar (US Regulatory)Amended Statement of Ownership (SC 13G/A)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
05/05/201017:10Edgar (US Regulatory)Quarterly Report (10-Q)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
05/05/201017:00Business WireAllos Therapeutics Reports First Quarter 2010 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
04/05/201016:22Edgar (US Regulatory)Confidential Treatment Order (CT ORDER)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
30/04/201007:06Edgar (US Regulatory)Proxy Statement (definitive) (DEF 14A)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
28/04/201018:40Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
27/04/201009:00Business WireAllos Therapeutics Appoints Dr. Charles Morris as Chief Medical OfficerNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
21/04/201009:00Business WireAllos Therapeutics to Report First Quarter 2010 Financial Results on May 5, 2010NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
09/04/201017:34Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (PRE 14A)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
01/03/201018:46Edgar (US Regulatory)Annual Report (10-K)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
01/03/201018:00Business WireAllos Therapeutics Reports Fourth Quarter and Full Year 2009 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
24/02/201011:01Business WireAllos Therapeutics to Participate in RBC Capital Markets Health Care ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
17/02/201011:00Business WireAllos Therapeutics to Report Fourth Quarter and Full Year 2009 Results on March 1, 2010NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
16/02/201020:35Edgar (US Regulatory)Annual Statement of Changes in Beneficial Ownership (5)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
16/02/201015:48Edgar (US Regulatory)Statement of Ownership (SC 13G)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
10/02/201016:25PR Newswire (US)MedNet Solutions Deploys Global Peripheral T-cell Lymphoma Registry for Allos TherapeuticsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/02/201011:00Business WireAllos Therapeutics to Present at BIO CEO & Investor ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
06/01/201011:00Business WireAllos Therapeutics to Present at J.P. Morgan Healthcare ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
11/12/200909:25MarketwiredWall St Sense Offers In-depth Research on the Services, Financial and Healthcare Sectors' Key PlayersNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
08/12/200912:15Business WireAllos Therapeutics’ FOLOTYN™ Shows Activity in a Dose Finding Phase 1 Study of Relapsed or Refractory Cutaneous T-Cell Ly...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
 Apresentando as notícias mais relevantes sobre:NASDAQ:ALTH

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
TELB4
TELEBRAS PN
BOV
MGLU3
MAGAZINE LUIZA ON
BOV
AZEV4
AZEVEDO PN
BOV
AERI3
Aeris Industria E Comerc... ON
BOV
HAGA3
HAGA ON
BOV
HBOR3
HELBOR ON
BOV
INBR32
Inter &
BOV
PRIO3
PETRORIO ON
BOV
GFSA3
GAFISA ON
BOV
AMER3
Americanas ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados